Clinical Trials Logo
  1. Home
  2. Other
  3. NCT02042560

Study of Immune Thrombocytopenia Pathogenesis: — PTI PARI  

Primary Immune Thrombocytopenia (ITP) Clinical Trial

Official title:
Study of Immune Thrombocytopenia Pathogenesis: a Multicenter, Open and Controlled Study.

Clinical Trial Summary

Immune thrombocytopenia (ITP) is an autoimmune disease characterized by a low platelet count responsible for bleedings. The disease is mostly mediated by antiplatelet antibodies produced by specific B cells. However, T cells are also involved but their role is not completely understood.

The aim of this study is to determine the implication of T cells in the pathogenesis of ITP, notably regulatory T cells (Treg, CD4+CD25highFoxp3+), cytotoxic T cells (CD3+CD8+) and T follicular helper cells (TFH, CD3+CD4+CXCR5+PD-1+ICOS+), in blood and in the spleen of primary ITP patients, compared to healthy controls.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • Primary Immune Thrombocytopenia (ITP)
  • Purpura, Thrombocytopenic, Idiopathic
  • Thrombocytopenia
Clinical Trial Details
NCT number NCT02042560
Study type Observational
Source Centre Hospitalier Universitaire Dijon
Contact
Status Completed
Phase N/A
Start date May 4, 2011
Completion date March 12, 2015
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04812483 - Immunomodulation With Eltrombopag in ITP Phase 2
Active, not recruiting NCT05029635 - Phase III Study on HMPL-523 for Treatment of ITP Phase 3
Completed NCT06408324 - Evaluation of the Use of Thrombopoietin Receptor Agonists in Adults With Primary ITP in Europe
Recruiting NCT05338190 - Efficacy and Safety of Subcutaneous Belimumab or Placebo in Addition of Rituximab in Persistent or Chronic Immune Thrombocytopenia Phase 3
Recruiting NCT05653349 - Study of Ianalumab Versus Placebo in Addition to First-line Corticosteroids in Primary Immune Thrombocytopenia (ITP) Phase 3
Withdrawn NCT04274452 - A Study to Assess the Efficacy and Safety of Efgartigimod in Adult Patients With Primary Immune Thrombocytopenia (ITP) Phase 3
Recruiting NCT05718856 - TPO-RAs Combining Anti-CD 20 Monoclonal Antibody Versus TPO-RAs in the Management of Pediatric Primary Immune Thrombocytopenia (ITP) Phase 4
Recruiting NCT05885555 - A Study of Ianalumab (VAY736) in Patients With Primary Immune Thrombocytopenia (ITP) Previously Treated With at Least Two Lines of Therapies Phase 2
Recruiting NCT04518475 - Eltrombopag Combining Rituximab Versus Eltrombopag in the Management of Primary Immune Thrombocytopenia (ITP) in Adults Phase 4